Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Ortiz-de-Solorzano C"'
Autor:
Lopez Janeiro A; IdiSNA, Pamplona, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Miraval Wong E; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Jiménez-Sánchez D; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Ortiz de Solorzano C; Program of Biomedical Engineering, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Lozano MD; IdiSNA, Pamplona, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Teijeira A; IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; CIMA, Immunology and Immunotherpay, Universidad de Navarra, Pamplona, Spain., Schalper KA; Pathology, Yale School of Medicine, New Haven, Connecticut, USA., Melero I; IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; CIMA, Immunology and Immunotherpay, Universidad de Navarra, Pamplona, Spain.; Nuffield Department of Medicine, Oxford University, Oxford, UK., De Andrea CE; IdiSNA, Pamplona, Spain ceandrea@unav.es.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 May 31; Vol. 12 (5). Date of Electronic Publication: 2024 May 31.
Publikováno v:
IEEE transactions on medical imaging [IEEE Trans Med Imaging] 2023 Oct; Vol. 42 (10), pp. 3048-3058. Date of Electronic Publication: 2023 Oct 02.
Prussian Blue nanoparticles: An FDA-approved substance that may quickly degrade at physiological pH.
Autor:
Doveri L; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: laviniarita.doveri01@universitadipavia.it., Dacarro G; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: giacomo.dacarro@unipv.it., Fernandez YAD; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: yuriantonio.diazfernandez@unipv.it., Razzetti M; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: matteo.razzetti96@gmail.com., Taglietti A; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: angelo.taglietti@unipv.it., Chirico G; Department of Physics 'G. Occhialini', University Milano-Bicocca, Piazza della Scienza, 3, 20126 Milano, Italy. Electronic address: giuseppe.chirico@unimib.it., Collini M; Department of Physics 'G. Occhialini', University Milano-Bicocca, Piazza della Scienza, 3, 20126 Milano, Italy. Electronic address: maddalena.collini@unimib.it., Sorzabal-Bellido I; Ciberonc, and Program of Biomedical Engineering, Center for Applied Medical Research (CIMA), University of Navarra, Av. de Pío XII, 55, 31008 Pamplona, Spain. Electronic address: ioritzsorzabal@gmail.com., Esparza M; Ciberonc, and Program of Biomedical Engineering, Center for Applied Medical Research (CIMA), University of Navarra, Av. de Pío XII, 55, 31008 Pamplona, Spain. Electronic address: maideresparza@unav.es., Ortiz-de-Solorzano C; Ciberonc, and Program of Biomedical Engineering, Center for Applied Medical Research (CIMA), University of Navarra, Av. de Pío XII, 55, 31008 Pamplona, Spain. Electronic address: codesolorzano@tecnun.es., Urteaga XM; Ciberonc, and Program of Biomedical Engineering, Center for Applied Medical Research (CIMA), University of Navarra, Av. de Pío XII, 55, 31008 Pamplona, Spain. Electronic address: xmorales@unav.es., Milanese C; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: chiara.milanese@unipv.it., Pallavicini P; Dipartimento di Chimica, Università degli Studi di Pavia, viale Taramelli, 12, 27100 Pavia, Italy. Electronic address: piersandro.pallavicini@unipv.it.
Publikováno v:
Colloids and surfaces. B, Biointerfaces [Colloids Surf B Biointerfaces] 2023 Jul; Vol. 227, pp. 113373. Date of Electronic Publication: 2023 May 26.
Autor:
Camacho-Gomez D; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Sorzabal-Bellido I; Solid Tumors and Biomarkers Program, IDISNA, and CIBERONC, Center for Applied Medical Research, University of Navarra, Zaragoza, Spain., Ortiz-de-Solorzano C; Solid Tumors and Biomarkers Program, IDISNA, and CIBERONC, Center for Applied Medical Research, University of Navarra, Zaragoza, Spain., Garcia-Aznar JM; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Gomez-Benito MJ; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
Publikováno v:
IScience [iScience] 2023 Jun 19; Vol. 26 (7), pp. 107164. Date of Electronic Publication: 2023 Jun 19 (Print Publication: 2023).
Autor:
Ortiz-Espinosa S; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Morales X; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Imaging Platform, CIMA, Pamplona, Spain., Senent Y; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Alignani D; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Cytometry Unit, Cima-University of Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Tavira B; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Macaya I; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain., Ruiz B; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain., Moreno H; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain., Remírez A; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Sainz C; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Rodriguez-Pena A; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Imaging Platform, CIMA, Pamplona, Spain., Oyarbide A; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Imaging Platform, CIMA, Pamplona, Spain., Ariz M; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Imaging Platform, CIMA, Pamplona, Spain., Andueza MP; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Valencia K; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Teijeira A; Program in Immunology and Immunotherapy, Cima-University of Navarra, Pamplona, Spain., Hoehlig K; Aptarion Biotech, Berlin, Germany., Vater A; Aptarion Biotech, Berlin, Germany., Rolfe B; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Queensland, Australia., Woodruff TM; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Queensland, Australia., Lopez-Picazo JM; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Vicent S; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain., Kochan G; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Immunomodulation Group, Navarrabiomed-Biomedical Research Center, Pamplona, Spain., Escors D; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Immunomodulation Group, Navarrabiomed-Biomedical Research Center, Pamplona, Spain., Gil-Bazo I; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Perez-Gracia JL; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Montuenga LM; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain., Lambris JD; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ortiz de Solorzano C; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Imaging Platform, CIMA, Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Lecanda F; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Ajona D; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain. Electronic address: dajonama@unav.es., Pio R; Program in Solid Tumors, Cima-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
Publikováno v:
Cancer letters [Cancer Lett] 2022 Mar 31; Vol. 529, pp. 70-84. Date of Electronic Publication: 2021 Dec 28.
Autor:
Otano I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain. iotanoan@alumni.unav.es.; H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital 12 de Octubre/ Spanish National Cancer Research Center (CNIO), Madrid, Spain. iotanoan@alumni.unav.es.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain. iotanoan@alumni.unav.es., Azpilikueta A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Medina-Echeverz J; Bavarian Nordic GmbH, Planegg, Germany., Cortés-Domínguez I; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Solid Tumours, Cima Universidad de Navarra, Pamplona, Spain., Ortiz-de-Solorzano C; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Program of Solid Tumours, Cima Universidad de Navarra, Pamplona, Spain., Ellmark P; Alligator Bioscience, Lund, Sweden.; Department of Immunotechnology, Lund University, Lund, Sweden., Fritzell S; Alligator Bioscience, Lund, Sweden., Hernandez-Hoyos G; Aptevo Therapeutics, Seattle, WA, USA., Nelson MH; Aptevo Therapeutics, Seattle, WA, USA., Ochoa MC; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Bolaños E; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Cuculescu D; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Jaúregui P; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Sanchez-Gregorio S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Etxeberria I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Rodriguez-Ruiz ME; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Teijeira Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain. imelero@unav.es.; H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital 12 de Octubre/ Spanish National Cancer Research Center (CNIO), Madrid, Spain. imelero@unav.es.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain. imelero@unav.es.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. imelero@unav.es.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain. imelero@unav.es.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. imelero@unav.es.
Publikováno v:
Nature communications [Nat Commun] 2021 Dec 15; Vol. 12 (1), pp. 7296. Date of Electronic Publication: 2021 Dec 15.
Autor:
de Andrea CE; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Ochoa MC; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Villalba-Esparza M; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Teijeira Á; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Schalper KA; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Abengozar-Muela M; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain., Eguren-Santamaría I; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Sainz C; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Sánchez-Gregorio S; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Garasa S; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Ariz M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Ortiz-de-Solorzano C; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Rodriguez-Ruiz ME; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Perez-Gracia JL; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Lozano MD; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain., Echeveste JI; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain., Sanmamed MF; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Melero I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain.
Publikováno v:
The Journal of pathology [J Pathol] 2021 Oct; Vol. 255 (2), pp. 190-201. Date of Electronic Publication: 2021 Aug 05.
Autor:
Morales X; IDISNA, Ciberonc and Solid Tumors and Biomarkers Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain., Cortés-Domínguez I; IDISNA, Ciberonc and Solid Tumors and Biomarkers Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain., Ortiz-de-Solorzano C; IDISNA, Ciberonc and Solid Tumors and Biomarkers Program, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.
Publikováno v:
Gels (Basel, Switzerland) [Gels] 2021 Feb 12; Vol. 7 (1). Date of Electronic Publication: 2021 Feb 12.
Autor:
Jericó D; Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain., Luis EO; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Neuroimaging Laboratory, CIMA, University of Navarra, 31008 Pamplona, Spain.; Theory and Methods Department Faculty of Education and Psychology, University of Navarra, 31008 Pamplona, Spain., Cussó L; Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain.; Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, 28911 Leganes, Spain.; Radiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain., Fernández-Seara MA; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Radiology, Clínica Universidad de Navarra School of Medicine Hospital, 31008 Pamplona, Spain., Morales X; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Imaging Platform, CIMA, University of Navarra, 31008 Pamplona, Spain., Córdoba KM; Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain., Benito M; Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain., Sampedro A; Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain., Larriva M; Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain., Ramírez MJ; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain., de Salamanca RE; Research Center, Hospital Universitario 12 de Octubre, Universidad Complutense, 28041 Madrid, Spain., Ortiz-de-Solorzano C; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Solid Tumors and Biomarkers Program, CIMA, University of Navarra, 31008 Pamplona, Spain., Alegre M; Neurophysiology Laboratory, Neuroscience Area, CIMA and Clínica Universidad de Navarra School of Medicine Hospital, University of Navarra, 31008 Pamplona, Spain., Prieto J; Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain., Lanciego JL; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Neurosciences Department, CIMA, University of Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNed), Instituto de Salud Carlos III, 28029 Madrid, Spain., D'Avola D; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Spain. Instituto de Salud Carlos III, 28029 Madrid, Spain.; Liver Unit, Clínica Universidad de Navarra, 31008 Pamplona, Spain., González-Aseguinolaza G; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Gene Therapy and regulation of Gene Expression program, CIMA, University of Navarra, 31008 Pamplona, Spain., Pastor MA; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Neuroimaging Laboratory, CIMA, University of Navarra, 31008 Pamplona, Spain., Desco M; Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain., Fontanellas A; Hepatology Program, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Spain. Instituto de Salud Carlos III, 28029 Madrid, Spain.
Publikováno v:
Human molecular genetics [Hum Mol Genet] 2020 Nov 25; Vol. 29 (19), pp. 3211-3223.
Autor:
Anguiano M; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Morales X; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Castilla C; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Pena AR; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Ederra C; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Martínez M; Neuroimaging Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Ariz M; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Esparza M; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Amaveda H; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Mora M; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Movilla N; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Aznar JMG; Department of Mechanical Engineering, Multiscale in Mechanical and Biological Engineering (M2BE), Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain., Cortés-Domínguez I; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Ortiz-de-Solorzano C; IDISNA, Ciberonc and Solid Tumours and Biomarkers Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Publikováno v:
PloS one [PLoS One] 2020 Jan 16; Vol. 15 (1), pp. e0220019. Date of Electronic Publication: 2020 Jan 16 (Print Publication: 2020).